CSTL
VENTE TOTALE: 59 788 titres (~1 818 733,45 $ US)
- Insiders
- MAETZOLD DEREK J
- Total bought
- —
- Total sold
- $1,818,733
- Last activity
- 2026-08-28
- Last synced
-
2026-09-03 09:53:14
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-03
CSTL presents a moderate setup: a solid earnings catalyst (strong Q2 beat, raised guidance, TissueCypher traction) with reasonable confidence (0.7) is partially offset by deteriorating fundamentals, including a return…
The first sentence of the analysis written for CSTL on 2026-09-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | |
| Ebit Margin | -8.5% | 6.7% | -26.1% | -50.3% | -42.5% | |
| Ebitda Margin | 3.3% | 11.5% | -20.5% | -42.6% | -38.9% | |
| Operating Profit Margin | -12.4% | 2.6% | -30.9% | -53.2% | -42.6% | |
| Pretax Profit Margin | -8.6% | 6.5% | -26.1% | -50.3% | -42.5% | |
| Continuous Operations Profit Margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | |
| Net Profit Margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | |
| Bottom Line Profit Margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | |
| Current Ratio | 5.258 | 7.292 | 6.202 | 8.090 | 14.215 | |
| Quick Ratio | 5.109 | 7.127 | 6.035 | 7.980 | 14.133 | |
| Solvency Ratio | 0.154 | 0.454 | -0.727 | -1.175 | -0.549 | |
| Cash Ratio | 1.700 | 2.424 | 2.074 | 3.403 | 13.246 | |
| Price To Earnings Ratio | -46.867 | 40.379 | -10.084 | -9.124 | -34.573 | |
| Price To Earnings Growth Ratio | 0.208 | -0.309 | 0.591 | -0.084 | -0.267 | |
| Forward Price To Earnings Growth Ratio | 0.208 | -0.309 | 0.591 | -0.084 | -0.267 | |
| Price To Earnings Diluted Ratio | -46.867 | 42.984 | -10.084 | -9.124 | -34.573 | |
| Price To Earnings Diluted Growth Ratio | 0.200 | -0.333 | 0.591 | -0.084 | -0.267 | |
| Price To Book Ratio | 2.395 | 1.624 | 1.478 | 1.537 | 2.617 | |
| Price To Sales Ratio | 3.276 | 2.229 | 2.632 | 4.475 | 11.454 | |
| Price To Free Cash Flow Ratio | 39.806 | 20.258 | -30.051 | -12.970 | -47.967 | |
| Price To Operating Cash Flow Ratio | 17.523 | 11.412 | -102.806 | -14.724 | -56.768 | |
| Debt To Assets Ratio | 0.064 | 0.050 | 0.034 | 0.030 | 0.018 | |
| Debt To Equity Ratio | 0.078 | 0.058 | 0.039 | 0.034 | 0.020 | |
| Debt To Capital Ratio | 0.073 | 0.055 | 0.038 | 0.032 | 0.020 | |
| Long Term Debt To Capital Ratio | 0.020 | 0.021 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.229 | 1.165 | 1.159 | 1.121 | 1.123 | |
| Working Capital Turnover Ratio | 1.141 | 1.189 | 0.872 | 0.468 | 0.255 | |
| Operating Cash Flow Ratio | 0.937 | 1.313 | -0.118 | -1.153 | -0.763 | |
| Operating Cash Flow Sales Ratio | 0.187 | 0.195 | -0.026 | -0.304 | -0.202 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.440 | 0.563 | 3.421 | 1.135 | 1.183 | |
| Debt Service Coverage Ratio | 33.199 | 40.724 | -4,102.273 | -3,328.118 | -27,884.000 | |
| Interest Coverage Ratio | -497.791 | 15.026 | -6,179.727 | -4,285.588 | -40,079.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 154.309 | 233.331 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 1.743 | 2.462 | -0.367 | -3.109 | -2.314 | |
| Capital Expenditure Coverage Ratio | 1.786 | 2.290 | -0.413 | -7.396 | -5.450 | |
| Dividend Paid And Capex Coverage Ratio | 1.786 | 2.290 | -0.413 | -7.396 | -5.450 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 92.369 | 16.961 | -10.991 | -8.634 | -20.659 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.4% | ▼-2.5% | ▼-0.8% |
| Ebit Margin | -8.6% | ▼-15.2% | ▲15.6% |
| Ebitda Margin | 3.3% | ▼-8.2% | ▲20.7% |
| Operating Profit Margin | -12.4% | ▼-15.0% | ▲14.9% |
| Pretax Profit Margin | -8.6% | ▼-15.1% | ▲15.6% |
| Continuous Operations Profit Margin | -7.0% | ▼-12.5% | ▲15.0% |
| Net Profit Margin | -7.0% | ▼-12.5% | ▲15.0% |
| Bottom Line Profit Margin | -7.0% | ▼-12.5% | ▲15.0% |
| Current Ratio | 5.258 | ▼-2.034 | ▼-2.953 |
| Quick Ratio | 5.109 | ▼-2.018 | ▼-2.968 |
| Solvency Ratio | 0.154 | ▼-0.300 | ▲0.523 |
| Cash Ratio | 1.700 | ▼-0.724 | ▼-2.869 |
| Price To Earnings Ratio | -46.867 | ▼-87.246 | ▼-34.814 |
| Price To Earnings Growth Ratio | 0.208 | ▲0.516 | ▲0.180 |
| Forward Price To Earnings Growth Ratio | 0.208 | ▲0.516 | ▲0.180 |
| Price To Earnings Diluted Ratio | -46.867 | ▼-89.851 | ▼-35.335 |
| Price To Earnings Diluted Growth Ratio | 0.200 | ▲0.534 | ▲0.179 |
| Price To Book Ratio | 2.395 | ▲0.771 | ▲0.465 |
| Price To Sales Ratio | 3.276 | ▲1.046 | ▼-1.538 |
| Price To Free Cash Flow Ratio | 39.806 | ▲19.548 | ▲45.991 |
| Price To Operating Cash Flow Ratio | 17.523 | ▲6.111 | ▲46.596 |
| Debt To Assets Ratio | 0.064 | ▲0.014 | ▲0.025 |
| Debt To Equity Ratio | 0.078 | ▲0.021 | ▲0.033 |
| Debt To Capital Ratio | 0.073 | ▲0.018 | ▲0.029 |
| Long Term Debt To Capital Ratio | 0.020 | ▼-0.001 | ▲0.012 |
| Financial Leverage Ratio | 1.229 | ▲0.063 | ▲0.069 |
| Working Capital Turnover Ratio | 1.141 | ▼-0.047 | ▲0.356 |
| Operating Cash Flow Ratio | 0.937 | ▼-0.376 | ▲0.894 |
| Operating Cash Flow Sales Ratio | 0.187 | ▼-0.008 | ▲0.217 |
| Free Cash Flow Operating Cash Flow Ratio | 0.440 | ▼-0.123 | ▼-0.908 |
| Debt Service Coverage Ratio | 33.199 | ▼-7.525 | ▲7081.292 |
| Interest Coverage Ratio | -497.791 | ▼-512.817 | ▲9707.625 |
| Short Term Operating Cash Flow Coverage Ratio | 154.309 | ▼-79.022 | ▲76.781 |
| Operating Cash Flow Coverage Ratio | 1.743 | ▼-0.719 | ▲2.060 |
| Capital Expenditure Coverage Ratio | 1.786 | ▼-0.504 | ▲3.623 |
| Dividend Paid And Capex Coverage Ratio | 1.786 | ▼-0.504 | ▲3.623 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 92.369 | ▲75.408 | ▲78.560 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.13B | $740.2M | $578.4M | $613.3M | $1.08B | |
| Enterprise value | $1.05B | $646.9M | $494.9M | $503.8M | $756.2M | |
| EV / Sales | 3.04x | 1.95x | 2.25x | 3.68x | 8.04x | |
| EV / Op. cash flow | 16.28x | 9.97x | -87.96x | -12.09x | -39.84x | |
| EV / Free cash flow | 36.99x | 17.70x | -25.71x | -10.65x | -33.66x | |
| EV / EBITDA | 92.37x | 16.96x | -10.99x | -8.63x | -20.66x | |
| Net debt / EBITDA | -7.04x | -2.45x | 1.85x | 1.88x | 8.78x | |
| Current ratio | 5.26x | 7.29x | 6.20x | 8.09x | 14.21x | |
| Income quality | -2.66x | 3.56x | 0.10x | 0.62x | 0.61x | |
| Graham number | — | $16 | — | — | — | |
| Graham net-net | $8 | $9 | $8 | $9 | $12 | |
| Tax burden | 81.9% | 84.6% | 100.2% | 97.4% | 78.2% | |
| Interest burden | 100.3% | 97.4% | 100.0% | 100.0% | 100.0% | |
| Working capital | $292.4M | $310.8M | $248.0M | $256.2M | $328.9M | |
| Invested capital | $504.2M | $479.7M | $403.0M | $409.0M | $434.7M | |
| Return on assets | -4.2% | 3.4% | -12.7% | -15.0% | -6.8% | |
| Operating ROA | -7.7% | 1.8% | -15.1% | -16.0% | -8.9% | |
| Return on tangible assets | -5.0% | 4.3% | -17.1% | -20.9% | -8.4% | |
| Return on equity | -5.1% | 4.0% | -14.7% | -16.8% | -7.6% | |
| Return on invested capital | -6.8% | 1.5% | -16.7% | -17.2% | -7.1% | |
| Return on capital employed | -8.4% | 1.8% | -16.8% | -17.7% | -9.2% | |
| Earnings yield | -2.1% | 2.5% | -9.9% | -10.9% | -2.9% | |
| Free cash flow yield | 2.5% | 4.9% | -3.3% | -7.7% | -2.1% | |
| Capex / Op. cash flow | 56.0% | 43.7% | -242.1% | -13.5% | -18.3% | |
| Capex / Depreciation | 88.3% | 177.1% | 110.5% | 53.4% | 102.2% | |
| Capex / Sales | 10.5% | 8.5% | 6.2% | 4.1% | 3.7% | |
| SG&A / Sales | 66.6% | 60.2% | 82.0% | 104.4% | 92.2% | |
| R&D / Sales | 15.1% | 15.7% | 24.4% | 32.8% | 31.5% | |
| Stock comp / Sales | 13.3% | 15.2% | 23.3% | 26.5% | 23.1% | |
| Intangibles / Total assets | 17.2% | 20.0% | 25.9% | 28.2% | 19.2% | |
| Days sales outstanding | 46d | 56d | 64d | 63d | 67d | |
| Days payables outstanding | 96d | 42d | 83d | 54d | 59d | |
| Operating cycle | 99d | 106d | 128d | 108d | 114d | |
| Cash conversion cycle | 3d | 64d | 45d | 54d | 55d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+52.3%EV / Sales ▲+56.3%EV / EBITDA ▲+444.6%EV / Op. cash flow ▲+6.310Earnings yield ▼-0.046
Profitability
Return on equity ▼-0.091Return on assets ▼-0.076Return on invested capital ▼-0.084Return on capital employed ▼-0.102Operating ROA ▼-0.095Income quality ▼-6.219Tax burden ▼-0.028
Efficiency
Days sales outstanding ▼-10.298Days payables outstanding ▲+54.314Operating cycle ▼-6.924Cash conversion cycle ▼-61.238Capex / Sales ▲+0.019R&D / Sales ▼-0.006
Balance-sheet strength
Current ratio ▼-2.034Net debt / EBITDA ▼-4.589Working capital ▼-18342000.000Invested capital ▲+24535000.000Intangibles / Total assets ▼-0.028
Change over 5 years
Valuation
Market cap ▲+4.6%EV / Sales ▼-62.1%EV / EBITDA ▲+547.1%EV / Op. cash flow ▲+56.118Earnings yield ▲+0.008
Profitability
Return on equity ▲+0.025Return on assets ▲+0.026Return on invested capital ▲+0.003Return on capital employed ▲+0.008Operating ROA ▲+0.012Income quality ▼-3.270Tax burden ▲+0.036
Efficiency
Days sales outstanding ▼-21.045Days payables outstanding ▲+37.418Operating cycle ▼-14.975Cash conversion cycle ▼-52.393Capex / Sales ▲+0.068R&D / Sales ▼-0.164
Balance-sheet strength
Current ratio ▼-8.957Net debt / EBITDA ▼-15.818Working capital ▼-36437000.000Invested capital ▲+69569000.000Intangibles / Total assets ▼-0.020
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-03-15 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-23 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-12-21 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-28 Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-25 Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect? The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-08-20 Castle Biosciences to Participate in Upcoming Investor Conferences FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird''s 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m.
- 2026-08-17 Castle Biosciences Approved for Dual Listing on Nasdaq Texas FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL.
- 2026-08-13 Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.
- 2026-08-04 Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL) Castle Biosciences (NASDAQ: CSTL - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Castle Biosciences
- 2026-07-31 Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript
- 2026-07-30 Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to earnings of $0.15 per share a year ago.
- 2026-07-30 Castle Biosciences Q2 Earnings Call Highlights Castle Biosciences NASDAQ: CSTL reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 million, from a previous range of $345 million to $355 million.
- 2026-07-22 Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time.